在前面的手稿中[Moreau et al。2018,10.1021 / acs.jmedchem.7b01691]我们描述了一个成功的基于片段的铅发现(FBLD)策略用于细菌磷酸泛酰腺苷酰转移酶抑制剂(PPAT,COAD)的发现。经过几轮优化,确定了两个有前途的先导化合物:三唑并嘧啶酮3和4-氮杂苯并咪唑4。在这里,我们公开了我们的工作,以进一步优化针对靶点效力和革兰氏阴性细胞活性的这两种线索。借助强大的X射线晶体学系统,我们基于结构的抑制剂设计方法可提供具有比其各自片段起始点大4–5个数量级的生化潜能的化合物。通过对细菌渗透性和理化性质的观察指导其他优化,这最终导致鉴定出具有针对野生型大肠杆菌的细胞活性的PPAT抑制剂。
[EN] O-GLCNAC TRANSFERASE INHIBITORS AND USES THEREOF<br/>[FR] INHIBITEURS DE LA O-GLCNAC TRANSFÉRASE ET LEURS UTILISATIONS
申请人:HARVARD COLLEGE
公开号:WO2020047251A1
公开(公告)日:2020-03-05
Provided herein are O-GlcNAc transferase (OGT) inhibitor compounds of Formula (I'), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, prodrugs, and compositions thereof. Also provided are methods and kits involving the inventive compounds or compositions for treating and/or preventing diseases (e.g., diabetes and complications thereof, neurodegenerative diseases, proliferative diseases such as cancers, autoimmune diseases, and inflammatory diseases) in a subject. Provided are methods of inhibiting OGT in a subject or biological sample.
Structure-Based Evolution of Low Nanomolar O-GlcNAc Transferase Inhibitors
作者:Sara E. S. Martin、Zhi-Wei Tan、Harri M. Itkonen、Damien Y. Duveau、Joao A. Paulo、John Janetzko、Paul L. Boutz、Lisa Törk、Frederick A. Moss、Craig J. Thomas、Steven P. Gygi、Michael B. Lazarus、Suzanne Walker
DOI:10.1021/jacs.8b07328
日期:2018.10.24
N-acetylglucosamine transferase (OGT), is responsible for all nucleocytoplasmic glycosylation and there is a well-known need for potent, cell-permeable inhibitors to interrogate OGT function. Here we report the structure-based evolution of OGT inhibitors culminating in compounds with low nanomolar inhibitory potency and on-target cellular activity. In addition to disclosing useful OGT inhibitors, the structures
Provided herein are O-GlcNAc transferase (OGT) inhibitor compounds of Formula (I), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, prodrugs, and compositions thereof. Also provided are methods and kits involving the inventive compounds or compositions for treating and/or preventing diseases (e.g., diabetes and complications thereof, neurodegenerative diseases, proliferative diseases such as cancers, autoimmune diseases, and inflammatory diseases) in a subject. Provided are methods of inhibiting OGT in a subject or biological sample.